Short interest for FibroGen gives investors a sense of the degree to which investors are betting on the decline of FibroGen's stock. Short interest data is updated every two weeks.

FibroGen Stock (NASDAQ:FGEN), Short Interest Report

FibroGen

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

Movers

News

Intraday Update

Markets

ADTN

AGRI

AIRE

AMBC

AORT

ATSG

AUDC

BAND

BLDR

BTBD

BYON

CMND

COKE

CROX

DAVE

DDOG

EVER

FGEN

FWRG

GLDD

GSUN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSDT

JELD

JJSF

JMIA

LCID

MSGM

NUVO

NUWE

PLTN

PLTR

PRGO

REAX

SELF

SGRY

STIM

STRL

TALK

TWKS

ZETA

Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

earnings stock ticker percentage

Earnings

FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents a 59.26% increase year-over-year. Quarterly sales clocked in at $55.902 million which beat the analyst consensus estimate of $36.666 million by 52.46% and is a significant increase over sales of $36.161 million from the same period last year.

FibroGen Shares Climb On Strong Q1 Sales

xr:d:DAFihZFI9kY:2,j:46857217386,t:23051013

Trading Ideas

IBRX

OTTR

SMMT

Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday

FibroGen Inc

Shares of Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) fell sharply during Tuesday&#8217;s session following weaker-than-expected <a href="https://www.benzinga.com/quote/BYON">quarterly results</a>.
Beyond posted adjusted loss of $1.22 per share, versus estimates for a loss of 87 cents per share. The company&#8217;s sales came in at $382.281 million versus estimates of $389.264 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Beyond shares dipped 20.8% to $17.34 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Golden Sun Health Technology Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSUN#NASDAQ">GSUN</a>) shares gained 94.7% to $5.60. Golden Sun Health Technology Group regained compliance with Nasdaq continued listing requirement.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) gained 79.1% to $4.1189.</li>
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares climbed 50.5% to $0.2572 after the company posted a narrower-than-expected quarterly loss.</li>
<li>Great Lakes Dredge &amp; Dock Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLDD#NASDAQ">GLDD</a>) rose 31.5% to $9.26 following better-than-expected first-quarter financial results.</li>
<li>American Strategic Investment Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYC#NYSE">NYC</a>) jumped 29.6% to $7.52.</li>
<li>Motorsport Games Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) gained 29.2% to $2.9493. Motorsport Games is expected to report its financial results for the first quarter of 2024 on Tuesday, May 7.</li>
<li>FibroGen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) surged 28.7% to $1.4899 after the company reported mixed first quarter financial results.</li>
<li>Bioventus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) rose 26.7% to $5.07 after the company reported better-than-expected first-quarter financial results and raised its FY24 guidance above estimates.</li>
<li>reAlpha Tech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) gained 25.1% to $1.0699 after the company announced the completion of its previously announced acquisition of Naamche.</li>
<li>Dave Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NYSE">DAVE</a>) gained 25% to $58.20 after the company reported better-than-expected first-quarter financial results and issued FY24 operating revenue.</li>
<li>Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) surged 24.8% to $1.46 after the company signed an exclusive patent licensing agreement with Yissum Research Development Company.</li>
<li>Thoughtworks Holding, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWKS#NASDAQ">TWKS</a>) jumped 22% to $3.0750 after the company issued strong guidance.</li>
<li>The Real Brokerage Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAX#NASDAQ">REAX</a>) gained 21.5% to $5.07 following strong quarterly sales.</li>
<li>Global Self Storage, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SELF#NASDAQ">SELF</a>) rose 21.2% to $5.05.</li>
<li>Zeta Global Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NASDAQ">ZETA</a>) rose 21% to $15.72 after the company reported better-than-expected first-quarter financial results and increased its second-quarter revenue guidance.</li>
<li>Jumia Technologies AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JMIA#NASDAQ">JMIA</a>) climbed 19.3% to $6.53 after the company reported a year-over-year increase in first-quarter revenue results.</li>
<li>Bandwidth Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAND#NASDAQ">BAND</a>) gained 19.2% to $24.45 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>ADTRAN Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>) climbed 18.4% to $5.58 following upbeat quarterly results.</li>
<li>Jumia Technologies AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JMIA#NASDAQ">JMIA</a>) gained 18.3% to $6.47 after the company reported a year-over-year increase in first-quarter revenue results.</li>
<li>Ambac Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBC#NYSE">AMBC</a>) shares rose 16.5% to $17.64 following better-than-expected first-quarter earnings.</li>
<li>FibroGen, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) gained 15.5% to $1.34 after the company reported mixed first-quarter financial results.</li>
<li>Sterling Infrastructure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) rose 15.1% to $121.27 after the company reported better-than-expected first-quarter financial results.</li>
<li>Coca-Cola Consolidated, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) jumped 14.5% to $981.96 following first-quarter results.</li>
<li>Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) gained 14% to $215.29 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance above estimates.</li>
<li>J&amp;J Snack Foods Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JJSF#NASDAQ">JJSF</a>) gained 13.5% to $156.51 following better-than-expected quarterly results.</li>
<li>Artivion, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) gained 13.4% to $23.90 following strong quarterly results.</li>
<li>EverQuote, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) gained 12.7% to $24.09 after the company reported better-than-expected first quarter financial results and issued second quarter revenue guidance above estimates.</li>
<li>Air Transport Services Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) rose 12.7% to $14.94 following upbeat earnings.</li>
<li>Surgery Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) gained 9.3% to $27.98 following upbeat earnings.</li>
<li>Crocs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) climbed 8.6% to $137.52 following first quarter financial results.</li>
<li>Symbotic Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NYSE">SYM</a>) shares rose 8.1% to $45.33 after the company reported mixed second-quarter financial results.</li>
<li>UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) shares gained 8% to $29.81 after the company posted better-than-expected results for its first quarter.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares gained 6.9% to $12.45 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Holdco Nuvo Group D.G Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVO#NASDAQ">NUVO</a>) fell 39.2% to $3.1999 after jumping 157% on Monday.</li>
<li>The Real Good Food Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGF#NASDAQ">RGF</a>) dipped 32.6% to $0.5312.</li>
<li>Neuronetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) fell 32.5% to $2.5281 following quarterly results.</li>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRI#NASDAQ">AGRI</a>) shares fell 27.4% to $0.1048 after the company announced an offering of 432.5 million shares by selling stockholders.</li>
<li>Strong Global Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGE#NYSE">SGE</a>) fell 27.4% to $1.9201. Fundamental Global announced acquisition of Strong/MDI Screen Systems, Inc. by FG Acquisition Corp. at a $30 million valuation.</li>
<li>GreenPower Motor Company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GP#NASDAQ">GP</a>) shares declined 25.6% to $1.35 after the company reported pricing of $2.3 million underwritten public offering.</li>
<li>JELD-WEN Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) fell 23.5% to $14.56 as the company posted downbeat quarterly sales and lowered 2024 revenue guidance.</li>
<li>Oriental Culture Holding LTD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCG#NASDAQ">OCG</a>) dipped 22.6% to $1.2001.</li>
<li>BT Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBD#NASDAQ">BTBD</a>) fell 21.4% to $1.25.</li>
<li>Plutonian Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTN#NASDAQ">PLTN</a>) shares fell 19.3% to $11.41 after surging 57% on Monday.</li>
<li>Talkspace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TALK#NASDAQ">TALK</a>) fell 18.3% to $2.60 following first-quarter results.</li>
<li>Helius Medical Technologies, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares declined 16.2% to $2.03 after the company announced pricing of $6.4 million public offering.</li>
<li>Paymentus Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) fell 15.5% to $18.76 following first-quarter results.</li>
<li>Myers Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) declined 15.5% to $19.43 following first-quarter results.</li>
<li>Builders FirstSource, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) dipped 15.4% to $170.00 following first-quarter earnings.</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) fell 14.3% to $21.56 following soft revenue guidance.</li>
<li>AudioCodes Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUDC#NASDAQ">AUDC</a>) shares fell 13% to $9.89 after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/AUDC/earnings">first-quarter financial results</a></li>
<li>First Watch Restaurant Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) dipped 12.6% to $21.96 following weak quarterly sales.</li>
<li>Teradata Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) dipped 11.4% to $33.63 after the company reported mixed first-quarter financial results and issued second-quarter guidance.</li>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares fell 11.2% to $2.71 after the company reported mixed first-quarter financial results.</li>
<li>The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) dipped 9.6% to $105.28 following a second-quarter revenue miss.</li>
<li>Methode Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) fell 9.4% to $11.37. Methode Electronics named Kevin Nystrom as interim CEO, effective immediately.</li>
<li>Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) fell 8.9% to $115.57 following first-quarter results.</li>
<li>Air Lease Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AL#NYSE">AL</a>) dipped 7.8% to $47.49 following weak quarterly sales.</li>
<li>Perrigo Company plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) fell 6.3% to $31.32 following weak quarterly sales.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38670858/dow-surges-over-50-points-disney-earnings-top-views">Dow Surges Over 50 Points; Disney Earnings Top Views</a>

Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

FibroGen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares are trading higher Tuesday after the company posted mixed first-quarter financial results. Here's a look at the <a href="https://www.benzinga.com/news/24/05/38672887/tempur-sealy-posts-upbeat-earnings-joins-fibrogen-coca-cola-consolidated-fabrinet-and-other-big-stoc">key figures from the report.</a>&nbsp;
The Details:
FibroGen reported q<a href="https://www.benzinga.com/pressreleases/24/05/g38652586/fibrogen-reports-first-quarter-2024-financial-results">uarterly losses</a> of 33 cents per share which missed the analyst consensus estimate of losses of 31 cents and represents a 59.26% increase year-over-year.&nbsp;
Quarterly sales clocked in at $55.902 million which beat the analyst consensus estimate of $36.666 million by 52.46% and is a significant increase over sales of $36.161 million from the same period last year.
The company reported first-quarter net revenue growth of 55% year over year, driven by strong roxadustat performance in China and one-time drug product revenue recognized from the US/RoW AstraZeneca agreement termination.&nbsp;
Cash, cash equivalents, investments, and accounts receivable were $214.7 million, and the company projected it has a cash runway into 2026.
&#8220;We are off to a strong start in 2024 marked by the recent release of compelling Phase 1 data on FG-3246, our CD46 targeted antibody drug conjugate, in metastatic castration-resistant prostate cancer and continued robust growth of our roxadustat business in China,&#8221; said Thane Wettig, CEO of FibroGen. &#8220;Looking ahead, we expect to report topline data from our two late-stage clinical trials of pamrevlumab in pancreatic cancer in the coming months. In addition, we have a strong balance sheet and reaffirm our cash runway into 2026.&#8221;
Related News: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38615880/whats-going-on-with-coinbase-stock-after-earnings">What&#8217;s Going On With Coinbase Stock After Earnings?</a>&nbsp;
<h2 class="wp-block-heading">Should I Sell My FGEN Stock? </h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of FibroGen have decreased by 92.53% in the past year. An investor who bought shares of FibroGen at the beginning of the year would make a profit of $0.47 per share if they sold it today. The stock has fallen 20.18% over the past month, meaning an investor who bought shares on April 1 would see a capital loss of $0.86.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. FibroGen stock currently has an RSI of 68.4, indicating neutral conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
FGEN Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, FibroGen shares are up 12.3% at $1.30 at the time of publication Tuesday.
Image: Gerd Altmann from Pixabay

U.S. stocks were higher, with the Dow Jones gaining over 80 points on Tuesday.
Shares of Tempur Sealy International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>) rose sharply during Tuesday's session <a href="https://www.benzinga.com/quote/TPX/earnings">following upbeat quarterly earnings</a>.
Tempur Sealy reported a first-quarter FY24 sales decline of 1.5% year-on-year to $1.189 billion, missing the analyst consensus estimate of $1.213 billion. Adjusted EPS of 50 cents beat the analyst consensus of 48 cents, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Tempur Sealy International shares gained 6.6% to $53.48 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Great Lakes Dredge &amp; Dock Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLDD#NASDAQ">GLDD</a>) shares jumped 31.5% to $9.26 following better-than-expected first-quarter financial results.</li>
<li>Dave Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NYSE">DAVE</a>) rose 25% to $58.20 after the company reported better-than-expected first-quarter financial results and issued FY24 operating revenue.</li>
<li>Thoughtworks Holding, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWKS#NASDAQ">TWKS</a>) climbed 22% to $3.0750 after the company issued strong guidance.</li>
<li>The Real Brokerage Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAX#NASDAQ">REAX</a>) rose 21.5% to $5.07 following strong quarterly sales.</li>
<li>Zeta Global Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NASDAQ">ZETA</a>) shares surged 21% to $15.72 after the company reported better-than-expected first-quarter financial results and increased its second-quarter revenue guidance.</li>
<li>Bandwidth Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAND#NASDAQ">BAND</a>) rose 19.2% to $24.45 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>ADTRAN Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>) rose 18.4% to $5.58 following upbeat quarterly results.</li>
<li>Jumia Technologies AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JMIA#NASDAQ">JMIA</a>) climbed 18.3% to $6.47 after the company reported a year-over-year increase in first-quarter revenue results.</li>
<li>Ambac Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBC#NYSE">AMBC</a>) shares rose 16.5% to $17.64 following better-than-expected first-quarter earnings.</li>
<li>FibroGen, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) climbed 15.5% to $1.34 after the company reported mixed first-quarter financial results.</li>
<li>Sterling Infrastructure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) gained 15.1% to $121.27 after the company reported better-than-expected first-quarter financial results.</li>
<li>Coca-Cola Consolidated, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) rose 14.5% to $981.96 following first-quarter results.</li>
<li>Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) jumped 14% to $215.29 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance above estimates.</li>
<li>J&amp;J Snack Foods Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JJSF#NASDAQ">JJSF</a>) rose 13.5% to $156.51 following better-than-expected quarterly results.</li>
<li>Artivion, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) rose 13.4% to $23.90 following strong quarterly results.</li>
<li>EverQuote, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) surged 12.7% to $24.09 after the company reported better-than-expected first quarter financial results and issued second quarter revenue guidance above estimates.</li>
<li>Air Transport Services Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) jumped 12.7% to $14.94 following upbeat earnings.</li>
<li>Surgery Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) rose 9.3% to $27.98 following upbeat earnings.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) climbed 9.3% to $8.54.</li>
<li>Crocs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) rose 8.6% to $137.52 following first quarter financial results.</li>
<li>Symbotic Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NYSE">SYM</a>) shares gained 8.1% to $45.33 after the company reported mixed second-quarter financial results.</li>
<li>Mueller Water Products, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MWA#NYSE">MWA</a>) rose 8.3% to $17.92 after the company reported better-than-expected seconc-quarter financial results and announced that Marietta Edmunds Zakas has been appointed Chief Executive Officer.</li>
<li>UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) shares rose 8% to $29.81 after the company posted better-than-expected results for its first quarter.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) gained 7% to $4.7550. Citigroup analyst Yigal Nochomovitz initiated coverage on Summit Therapeutics with a Buy rating and announced a price target of $7.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares rose 6.9% to $12.45 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Otter Tail Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTTR#NASDAQ">OTTR</a>) jumped 5.9% to $96.00 following first-quarter earnings.</li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) gained 5.3% to $74.17 as the company reported better-than-expected first-quarter financial results and announced a $500 million increase to 2024 share repurchase goal.</li>
<li>NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) gained 5.1% to $81.86 following upbeat earnings.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38667879/jim-cramer-calls-nutanix-the-perfect-enterprise-software-company-for-the-moment">Jim Cramer Calls Nutanix &#8216;The Perfect Enterprise Software Company For The Moment&#8217;</a>

Shares of Zeta Global Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NASDAQ">ZETA</a>) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and increased its <a href="https://www.benzinga.com/quote/ZETA/earnings">second-quarter revenue guidance</a>.
Zeta Global posted GAAP loss of 23 cents per share, compared to market expectations for a loss of 25 cents per share. The company's quarterly sales came in at $194.947 million topping estimates of $187.112 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Zeta Global shares jumped 15.3% to $15.00 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>reAlpha Tech Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) gained 65.8% to $1.42 in pre-market trading after the company announced the completion of its previously announced acquisition of Naamche.</li>
<li>FibroGen, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) gained 27.5% to $1.48 in pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) rose 26.8% to $1.84 in today's pre-market trading. TC BioPharm recently the execution of a non-binding letter of intent to acquire a company pursuing the development of innovative CAR-T thera.</li>
<li>Ambac Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBC#NYSE">AMBC</a>) shares rose 19.1% to $18.00 in pre-market trading following better-than-expected first-quarter earnings.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares gained 16.4% to $13.57 in pre-market trading after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Fundamental Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGF#NASDAQ">FGF</a>) jumped 15.3% to $1.51 in pre-market trading after the company announced the acquisition of Strong/MDI Screen Systems by FG Acquisition Corp. at a $30 million valuation.</li>
<li>T2 Biosystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares gained 11.3% to $4.04 in pre-market trading after the company reported mixed first-quarter financial results and announced the execution of a territory exclusive distribution agreement in Qatar.</li>
<li>Symbotic Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NYSE">SYM</a>) shares rose 11.7% to $46.85 in pre-market trading after the company reported mixed second-quarter financial results.</li>
<li>UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) shares gained 7.6% to $29.70 in pre-market trading after the company posted better-than-expected results for its first quarter.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>AgriFORCE Growing Systems Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRI#NASDAQ">AGRI</a>) fell 34% to $0.0953 in pre-market trading after the company filed for offering of up to 432.5 million shares by selling stockholders.</li>
<li>GreenPower Motor Company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GP#NASDAQ">GP</a>) shares declined 28.6% to $1.30 in pre-market trading after the company reported pricing of $2.3 million underwritten public offering.</li>
<li>mF International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>) shares fell 20.2% to $0.9575 in pre-market trading after dipping 10% on Monday.</li>
<li>Strong Global Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGE#NYSE">SGE</a>) fell 15.1% to $2.25 pre-market trading. Fundamental Global announced acquisition of Strong/MDI Screen Systems, Inc. by FG Acquisition Corp. at a $30 million valuation.</li>
<li>Holdco Nuvo Group D.G Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVO#NASDAQ">NUVO</a>) fell 13.7% to $4.53 in pre-market trading after jumping 157% on Monday.</li>
<li>Plutonian Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTN#NASDAQ">PLTN</a>) shares fell 12.8% to $8.32 in pre-market trading after surging 57% on Monday.</li>
<li>Trupanion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) shares declined 13% to $20.68 in pre-market trading following first-quarter results.</li>
<li>AudioCodes Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUDC#NASDAQ">AUDC</a>) shares fell 11.3% to $10.10 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Helius Medical Technologies, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares declined 9.9% to $2.18 in pre-market trading after the company announced pricing of $6.4 million public offering.</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) fell 9.3% to $22.85 pre-market trading following soft revenue guidance.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38661451/disney-electronic-arts-and-3-stocks-to-watch-heading-into-tuesday">Disney, Electronic Arts And 3 Stocks To Watch Heading Into Tuesday</a>

Pre-Market Outlook

TCBP

TRUP

TTOO

Why Zeta Global Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares rose 37.1% to $1.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $158.1 million. The company's, Q1 earnings came out yesterday. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock moved upwards by 23.54% to $4.25. The company's market cap stands at $83.2 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 21.18% to $0.33. The company's market cap stands at $3.0 million. The company's, Q1 earnings came out today. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) shares moved upwards by 20.87% to $0.11. The company's market cap stands at $3.9 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares rose 19.25% to $3.84. The market value of their outstanding shares is at $5.3 million. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) stock increased by 18.39% to $2.51. The company's market cap stands at $475.3 million. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares decreased by 16.5% to $2.02 during Tuesday's pre-market session. The company's market cap stands at $1.7 million. </li>
<li>Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) shares declined by 11.05% to $2.98. The company's market cap stands at $214.4 million. </li>
<li>Eledon Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELDN#NASDAQ">ELDN</a>) shares fell 9.43% to $2.21. The market value of their outstanding shares is at $54.8 million. </li>
<li>Fresenius Medical Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) stock fell 8.03% to $19.7. The company's market cap stands at $11.5 billion. </li>
<li>Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) shares declined by 7.42% to $218.1. The market value of their outstanding shares is at $4.6 billion. The company's, Q1 earnings came out today. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) shares declined by 7.31% to $1.65. The company's market cap stands at $26.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLLS

CNTX

Envoy Medical, Inc. - Class A Common Stock

COCH

ELDN

ESPR

GTBP

ISPC

MDGL

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

WIIM

FibroGen shares are trading higher after the company reported mixed Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares rose 23.0% to $0.32 during Monday's after-market session. The market value of their outstanding shares is at $24.9 million. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares increased by 20.68% to $1.4. The market value of their outstanding shares is at $139.2 million. As per the news, the Q1 earnings report came out today. </li>
<li>RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) shares rose 11.39% to $70.0. The company's market cap stands at $2.6 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares increased by 10.81% to $0.25. The market value of their outstanding shares is at $3.2 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares increased by 10.72% to $12.9. The company's market cap stands at $2.7 billion. As per the press release, Q1 earnings came out today. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock increased by 8.58% to $0.3. The company's market cap stands at $2.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) shares decreased by 9.1% to $1.6 during Monday's after-market session. The market value of their outstanding shares is at $6.5 million. </li>
<li>SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) shares fell 6.77% to $13.5. The company's market cap stands at $556.2 million. As per the news, the Q1 earnings report came out today. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock fell 5.68% to $0.25. The company's market cap stands at $7.2 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) stock declined by 5.28% to $0.24. The market value of their outstanding shares is at $11.2 million. </li>
<li>Clene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) shares declined by 5.15% to $0.4. The company's market cap stands at $51.6 million. </li>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) shares fell 4.96% to $2.3. The market value of their outstanding shares is at $150.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATPC

AZTR

CLNN

LUCY

OTRK

POAI

RGLS

RXST

SIBN

12 Health Care Stocks Moving In Monday's After-Market Session

FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.31) by 6.45 percent. This is a 59.26 percent increase over losses of $(0.81) per share from the same period last year. The company reported quarterly sales of $55.902 million which beat the analyst consensus estimate of $36.666 million by 52.46 percent. This is a 54.59 percent increase over sales of $36.161 million the same period last year.

Earnings Beats

Earnings Misses

FibroGen Q1 2024 GAAP EPS $(0.33) Misses $(0.31) Estimate, Sales $55.902M Beat $36.666M Estimate

Biotech

General

FibroGen To Present Data From Dose Escalation Phase 1b Study of FG-3246 Plus Enzalutamide At 2024 American Society of Clinical Oncology Annual Meeting May 31-Jun. 4

FibroGen shares are trading lower after the company announced topline results from the Phase 1 monotherapy study of FG-3246 in patients with metastatic castration-resistant prostate cancer.

Shares of Ulta Beauty, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ulta#NASDAQ">ULTA</a>) fell sharply during Wednesday&rsquo;s session amid the company&#39;s presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly issued a weak outlook.
Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>ARCA biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abio#NASDAQ">ABIO</a>) climbed 108% to $3.5549 after the company and Oruka Therapeutics announced a merger agreement.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) shares gained 89% to $0.1906 after the company entered a merger agreement with TuHURA Biosciences.</li>
<li>Next Technology Holding Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxtt#NASDAQ">NXTT</a>) rose 57.4% to $6.42.</li>
<li>Vanda Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vnda#NASDAQ">VNDA</a>) shares climbed 39.3% to $5.45. Vanda Pharmaceuticals&#39; Fanapt&reg; received U.S. FDA approval for the acute treatment of Bipolar I Disorder.</li>
<li>VivoPower International PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vvpr#NASDAQ">VVPR</a>) shares gained 39% to $8.20 after the company declared a capital management strategy including a stock buyback program of up to $5 million.</li>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) gained 32.7% to $0.0345.</li>
<li>XTI Aerospace, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xtia#NASDAQ">XTIA</a>) rose 32.2% to $4.63. BestGrowthStocks.com issued comprehensive evaluation of XTI Aerospace, Inc.</li>
<li>Brooge Energy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brog#NASDAQ">BROG</a>) gained 28.8% to $3.0790.</li>
<li>Addex Therapeutics Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adxn#NASDAQ">ADXN</a>) rose 24.6% to $16.21 after the company and funds affiliated with Perceptive Advisors announced the launch of Neurosterix.</li>
<li>Aesthetic Medical International Holdings Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aih#NASDAQ">AIH</a>) gained 24.3% to $0.3981 after gaining 13% on Tuesday.</li>
<li>LAMF Global Ventures Corp. I (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvc#NASDAQ">LGVC</a>) gained 22.7% to $13.21. ViewLAMF Global Ventures Corp. I shareholders approved previously announced business combination with Nuvo Group Ltd.</li>
<li>Quhuo Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qh#NASDAQ">QH</a>) rose 21.7% to $0.6501 after reporting unaudited financial results for the second half and full year 2023.</li>
<li>Destiny Tech100 Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NYSE">DXYZ</a>) gained 21.4% to $25.77.</li>
<li>OneMedNet Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onmd#NASDAQ">ONMD</a>) gained 21.2% to $0.9600. OneMedNet announced it entered a securities purchase agreement dated Mar. 28 providing up to $4.54 million in funding through private placement of senior convertible notes.</li>
<li>CXApp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cxai#NASDAQ">CXAI</a>) gained 20.5% to $5.40 following a massive rally to start the week. CXApp shares rallied more than 150% to start the week after the company announced a partnership with Alphabet&rsquo;s Google Cloud.</li>
<li>Clean Energy Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cety#NASDAQ">CETY</a>) climbed 20.5% to $1.63.</li>
<li>American Battery Technology Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abat#NASDAQ">ABAT</a>) rose 17.7% to $1.9301. American Battery Technology Company was awarded $20 million tax credit through competitive U.S. DOE process to advance its critical minerals battery recycling facility.</li>
<li>C3is Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) shares rose 14.9% to $0.0470 after gaining 13% on Tuesday. On March 26, C3is reported a year-over-year increase in fourth-quarter financial results.</li>
<li>Pyxis Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pyxs#NASDAQ">PYXS</a>) gained 12.3% to $6.04.</li>
<li>Atai Life Sciences N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atai#NASDAQ">ATAI</a>) surged 11.4% to $2.08. Maxim Group analyst Jason McCarthy upgraded ATAI Life Sciences from Hold to Buy and announced a $6 price target.</li>
<li>Dave &amp; Buster&#39;s Entertainment, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/play#NASDAQ">PLAY</a>) shares rose 10.2% to $68.22 after the company reported fourth quarter results.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) jumped 9.7% to $3.16.</li>
<li>Signet Jewelers Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sig#NYSE">SIG</a>) gained 9.2% to $103.80after the company raised its FY25 guidance.</li>
<li>Inspire Veterinary Partners, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ivp#NASDAQ">IVP</a>) gained 9% to $0.0512. On Jan. 5, Inspire Veterinary Partners filed a prospectus related to up to a $5 million public offering.</li>
<li>Semtech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smtc#NASDAQ">SMTC</a>) gained 7.4% to $30.28.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calm#NASDAQ">CALM</a>) climbed 6.8% to $62.88 after the company reported upbeat results for its fourth quarter.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Casa Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/casa#NASDAQ">CASA</a>) shares dipped 78.1% to $0.0563 after the Company filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court.</li>
<li>View, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/view#NASDAQ">VIEW</a>) fell 61.9% to $0.4196 after the company filed for Chapter 11 bankruptcy. The company on Tuesday said it reached a real with Cantor Fitzgerald and RXR to become a private company.</li>
<li>Sintx Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sint#NASDAQ">SINT</a>) fell 44.5% to $0.0232 after the company announced pricing of a $1.5 million public offering of common stock.</li>
<li>GCT Semiconductor Holding, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gcts#NYSE">GCTS</a>) dipped 40% to $9.29 amid volatility following the company&#39;s recently completed business combination with Concord Acquisition Corp III and NYSE debut.</li>
<li>FibroGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fgen#NASDAQ">FGEN</a>) fell 32.8% to $1.4499. FibroGen announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with an MMAE-containing payload.</li>
<li>Keyarch Acquisition Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kych#NASDAQ">KYCH</a>) fell 28.5% to $9.65.</li>
<li>TRACON Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>) dipped 24.2% to $0.3148 as the company issued an update on ongoing ENVASARC Phase 2 pivotal trial following Independent Data Monitoring Committee Recommendation to continue the trial as planned.</li>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) fell 22.5% to $0.9741 after dipping around 12% on Tuesday.</li>
<li>Anghami Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/angh#NASDAQ">ANGH</a>) fell 22.2% to $1.40. Anghami recently announced that it completed its transaction with OSN+.</li>
<li>Locafy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lcfy#NASDAQ">LCFY</a>) dipped 21.9% to $3.67 following second-quarter results.</li>
<li>Vicinity Motor Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vev#NASDAQ">VEV</a>) fell 19.3% to $0.75 after the company reported a year-over-year decrease in fourth-quarter EPS results.</li>
<li>Enveric Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/envb#NASDAQ">ENVB</a>) dipped 18.4% to $0.93.</li>
<li>Murano Global Investments Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrno#NASDAQ">MRNO</a>) fell 16.8% to $10.39.</li>
<li>Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) fell 16.7% to $11.66.</li>
<li>Acorda Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acor#NASDAQ">ACOR</a>) shares fell 12% to $2.20. Acorda Therapeutics shares dipped 81% on Tuesday after the company commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code.</li>
<li>Exscientia plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exai#NASDAQ">EXAI</a>) fell 10.8% to $4.6395 following quarterly results.</li>
<li>Gamida Cell Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmda#NASDAQ">GMDA</a>) shares fell 8.4% to $0.0403 after gaining 18% on Tuesday.</li>
<li>e.l.f. Beauty, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/elf#NYSE">ELF</a>) fell 8.2% to $170.71 after peer Ulta Beauty reportedly issued weak guidance at a conference.</li>
<li>NWTN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nwtn#NASDAQ">NWTN</a>) fell 8% to $7.21.</li>
<li>Mesoblast Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>) shares tumbled 7.3% to $6.11 after gaining 8% on Tuesday.</li>
<li>Applied Digital Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apld#NASDAQ">APLD</a>) fell 6.1% to $3.5850.</li>
<li>Lands&#39; End, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/le#NASDAQ">LE</a>) fell 6.1% to $11.25.</li>
<li>Intel Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intc#NASDAQ">INTC</a>) fell 6.1% to $41.27 after the company outlined a new financial framework for its foundry business. After the market close on Tuesday, Intel announced a new financial reporting structure designed to drive increased cost discipline and higher returns by providing greater transparency, accountability and incentives across the business.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38069445/ethereum-trades-below-3-400-following-adp-report-stacks-becomes-top-loser"> Ethereum Trades Below $3,400 Following ADP Report; Stacks Becomes Top Loser</a>

Penny Stocks

Small Cap

ABAT

ABIO

ACOR

ADXN

ANGH

APLD

ATAI

BCAN

BROG

CALM

CASA

CETY

CISS

CRML

CXAI

DXYZ

EGOX

ENVB

EXAI

GCTS

GMDA

INTC

Kintara Therapeutics, Inc. - Common Stock

KTRA

KYCH

LCFY

LGVC

MESO

MRNO

NWTN

Next Technology Holding Inc. - Ordinary Shares

NXTT

ONMD

PLAY

PYXS

SINT

SMTC

TCON

ULTA

VIEW

VNDA

VVPR

XTIA

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>ARCA biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABIO#NASDAQ">ABIO</a>) shares moved upwards by 84.8% to $3.16 during Wednesday's regular session. The market value of their outstanding shares is at $45.8 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock moved upwards by 71.81% to $0.17. The market value of their outstanding shares is at $6.7 million. </li>
<li>Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) shares rose 39.38% to $5.45. The market value of their outstanding shares is at $313.5 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares moved upwards by 29.67% to $0.11. The company's market cap stands at $10.5 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) shares moved upwards by 27.0% to $3.01. The company's market cap stands at $117.1 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock increased by 24.99% to $5.6. The company's market cap stands at $109.4 million. As per the news, the Q4 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock decreased by 44.5% to $0.02 during Wednesday's regular session. The company's market cap stands at $1.1 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) stock declined by 35.4% to $0.27. The company's market cap stands at $12.2 million. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares declined by 32.64% to $1.46. The company's market cap stands at $143.7 million. </li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) shares declined by 22.41% to $1.94. The company's market cap stands at $2.4 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares fell 16.18% to $1.14. The market value of their outstanding shares is at $4.8 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares fell 15.33% to $0.57. The market value of their outstanding shares is at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

BRNS

BSGM

SBFM

12 Health Care Stocks Moving In Wednesday's Intraday Session

FibroGen Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with an&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38060094/fibrogen-announces-topline-results-from-phase-1-monotherapy-study-of-fg-3246-in-patients-with-meta" rel="noreferrer noopener">MMAE-containing payload</a>.
In a dose-escalation and dose-expansion trial, the study enrolled patients with metastatic castration-resistant prostate cancer whose tumors have progressed on at least one androgen receptor-signaling inhibitor.
In the efficacy analysis, prostate-specific antigens (PSA) reductions of over 50% were observed in 36% of PSA evaluable patients.&nbsp;
20% met the criteria of a partial response, or tumor reduction in size of over 30%, with a median duration of response of 7.5 months. The median radiographic progression-free survival (rPFS) in this heavily pretreated patient population was 8.7 months.
The most frequent adverse events were consistent with other MMAE-based ADCs and included infusion-related reactions, fatigue, weight loss, neutropenia, and peripheral neuropathy.
William Blair&nbsp;writes that initial FG-3246 results appear to offer numerically improved efficacy metrics relative to alternate novel hormone therapy.&nbsp;
Although the FDA advises against drawing definitive conclusions solely from the point estimate of progression-free survival in single-arm studies, suggesting it be interpreted alongside hazard ratios, William Blair advocates for additional exploration of FG-3246 in prostate cancer due to the study&#8217;s heavily pretreated participants and inclusion of an unselected population.
William Blair writes that the company plans to enhance the therapeutic effectiveness of FG-3246 in two key ways:
<ul>
<li>Firstly, it will utilize a dosing scheme based on adjusted body weight, inspired by&nbsp;AbbVie Inc&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) approach with Elahere in ovarian cancer treatment.&nbsp;</li>
<li>Secondly, it will utilize an imaging agent called 89Zr-based CD46 PET to select patients most likely to benefit from FG-3246 in the Phase 2 study.&nbsp;</li>
</ul>
FibroGen management intends to consult with the FDA about the development pathway and commence the Phase 2 study in the latter half of the year.
Price Action: FGEN shares are down 18.30% at $1.77 on the last check Wednesday.

Analyst Color

Health Care

Analyst Ratings

ABBV

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape

In the efficacy analysis, PSA reductions of &ge;&nbsp;50%&nbsp;were observed in&nbsp;36%&nbsp;of PSA evaluable patients. For RECIST evaluable patients,&nbsp;20%&nbsp;met the criteria of a partial response, or tumor reduction in size of &ge;&nbsp;30%, with a median duration of response of 7.5 months. The median rPFS in this heavily pre-treated patient population was 8.7 months.&nbsp;Company plans to meet with the U.S. Food and Drug Administration (FDA) to discuss development pathway; Phase 2 initiation is anticipated in 2H 2024

FibroGen Reports Data From Fortis Therapeutics-Sponsored Phase 1 Study Of FG-3246

The Dow Jones index closed higher by around 47 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>FibroGen </h3>
<ul>
<li>The Trade: FibroGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fgen#NASDAQ">FGEN</a>) CEO Thane Wettig <a href="https://www.benzinga.com/quote/FGEN/analyst-ratings"> acquired a total of 50,000 shares </a> an average price of $1.91. To acquire these shares, it cost around $95,470.</li>
<li>What&rsquo;s Happening: On March 11, FibroGen named Deyaa Adib, M.D. as Chief Medical Officer.</li>
<li>What FibroGen Does: FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia.</li>
</ul>
<h3>RealReal</h3>
<ul>
<li>The Trade: The RealReal, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/real#NASDAQ">REAL</a>) Director Karen Katz <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 6,500 shares at </a> at an average price of $3.85. To acquire these shares, it cost around $25,025.</li>
<li>What&rsquo;s Happening: On Feb. 29, RealReal reported better-than-expected fourth-quarter financial results and issued FY24 revenue guidance.</li>
<li>What RealReal Does: The RealReal is the largest pure-play luxury resale platform in the US, generating $1.7 billion in 2023 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/03/37584146/top-5-risk-off-stocks-that-may-plunge-this-quarter"> Top 5 Risk Off Stocks That May Plunge This Quarter </a>
<h3>Outlook Therapeutics </h3>
<ul>
<li>The Trade: Outlook Therapeutics, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otlk#NASDAQ">OTLK</a>) Chief Commercial Officer Jeff Evanson <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 62,484 shares </a> at an average price of $0.42. The insider spent around $26,243 to buy those shares.</li>
<li>What&rsquo;s Happening: On Feb. 14, Outlook Therapeutics posted a narrower-than-expected quarterly loss.</li>
<li>What Outlook Therapeutics Does: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.</li>
</ul>
<h3>Globalstar </h3>
<ul>
<li>The Trade: Globalstar, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gsat#NASDAQ">GSAT</a>) Director James F Lynch <a href="https://www.benzinga.com/quote/GSAT/analyst-ratings"> acquired a total of 1,320,000 shares </a> at an average price of $1.32. The insider spent around $1.75 million to buy those shares.</li>
<li>What&rsquo;s Happening: On Feb. 28, Globalstar reported worse-than-expected fourth-quarter sales results and issued FY24 total revenue guidance below estimates.</li>
<li>What Globalstar Does: Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Long Ideas

Insider Trades

GSAT

OTLK

REAL

Over $1.7M Bet On Globalstar? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) reported its Q4 earnings results on Monday, February 26, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
FibroGen missed estimated earnings by -36.0%, reporting an EPS of $-0.57 versus an estimate of $-0.42.
Revenue was down $7.23 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.16 which was followed by a 1.0% drop in the share price the next day.
Here's a look at FibroGen's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.68</td>
<td>-0.72</td>
<td>-0.75</td>
<td>-0.94</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.52</td>
<td>-0.90</td>
<td>-0.81</td>
<td>-0.70</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>36.84M</td>
<td>34.17M</td>
<td>31.84M</td>
<td>24.04M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>40.13M</td>
<td>44.32M</td>
<td>36.16M</td>
<td>34.37M</td>
</tr>
</tbody>
</table>

To track all earnings releases for FibroGen <a href="https://www.benzinga.com/quote/FGEN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: FibroGen Q4 Earnings

FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.42) by 35.71 percent. The company reported quarterly sales of $27.14 million which missed the analyst consensus estimate of $38.90 million by 30.24 percent. This is a 21.04 percent decrease over sales of $34.37 million the same period last year.

FibroGen Q4 2023 GAAP EPS $(0.57) Misses $(0.42) Estimate, Sales $27.14M Miss $38.90M Estimate

FibroGen And AstraZeneca Agree To Terminate Roxadustat Collaboration Agreement Entered On Jul. 30, 2013; FibroGen Regains All Rights To Roxadusta In United States And Other AstraZeneca Territories, Except China And South Korea

<h3>Companies Reporting Before The Bell</h3>
&bull; Kosmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
&bull; Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) is estimated to report quarterly loss at $0.37 per share on revenue of $28.61 million.
&bull; Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $5.48 billion.
&bull; Clear Channel Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $610.14 million.
&bull; Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $96.20 million.
&bull; BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) is projected to report quarterly loss at $0.24 per share on revenue of $90.01 million.
&bull; Fresh Del Monte Produce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $1.03 billion.
&bull; Gilat Satellite Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $75.98 million.
&bull; Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $570.23 million.
&bull; Playtika Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTK#NASDAQ">PLTK</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $629.98 million.
&bull; Enlight Renewable Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLT#NASDAQ">ENLT</a>) is projected to report earnings for its Fiscal Year 2023.
&bull; Surgery Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $741.40 million.
&bull; Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) is projected to report quarterly earnings at $9.07 per share on revenue of $796.65 million.
&bull; Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $1.00 billion.
&bull; Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $204.36 million.
&bull; Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) is likely to report earnings for its fourth quarter.
&bull; Public Service Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $2.40 billion.
&bull; Domino&#39;s Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) is likely to report quarterly earnings at $4.37 per share on revenue of $1.42 billion.
&bull; Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) is expected to report quarterly earnings at $0.94 per share on revenue of $2.53 billion.
&bull; Pilgrims Pride (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) is estimated to report quarterly earnings at $0.40 per share on revenue of $4.47 billion.
&bull; Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is expected to report quarterly loss at $0.12 per share on revenue of $5.21 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) is likely to report earnings for its fourth quarter.
&bull; Diversified Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHC#NASDAQ">DHC</a>) is likely to report earnings for its fourth quarter.
&bull; Franklin Street Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSP#AMEX">FSP</a>) is likely to report earnings for its fourth quarter.
&bull; Dril-Quip (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRQ#NYSE">DRQ</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $118.50 million.
&bull; Revolution Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) is likely to report quarterly loss at $0.90 per share on revenue of $1.09 million.
&bull; FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) is expected to report quarterly loss at $0.42 per share on revenue of $38.90 million.
&bull; Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) is likely to report quarterly loss at $0.32 per share on revenue of $29.84 million.
&bull; Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $75.89 million.
&bull; Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) is projected to report earnings for its fourth quarter.
&bull; Aarons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAN#NYSE">AAN</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $542.07 million.
&bull; Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) is likely to report quarterly loss at $0.28 per share on revenue of $320 thousand.
&bull; ATI Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATIP#NYSE">ATIP</a>) is projected to report quarterly loss at $3.74 per share on revenue of $177.39 million.
&bull; Air Transport Services Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) is expected to report quarterly earnings at $0.28 per share on revenue of $523.06 million.
&bull; CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) is likely to report quarterly earnings at $0.34 per share on revenue of $220.05 million.
&bull; Dorman Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DORM#NASDAQ">DORM</a>) is likely to report quarterly earnings at $1.41 per share on revenue of $496.72 million.
&bull; Ellington Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFC#NYSE">EFC</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $42.67 million.
&bull; Erie Indemnity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>) is likely to report quarterly earnings at $2.02 per share on revenue of $772.57 million.
&bull; Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) is estimated to report quarterly loss at $0.52 per share on revenue of $1.59 million.
&bull; Helix Energy Solns Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $315.60 million.
&bull; AES (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) is estimated to report quarterly earnings at $0.67 per share on revenue of $3.36 billion.
&bull; Carlyle Secured Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBD#NASDAQ">CGBD</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $56.74 million.
&bull; iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) is projected to report quarterly loss at $2.11 per share on revenue of $307.99 million.
&bull; Douglas Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLOW#NYSE">PLOW</a>) is estimated to report quarterly loss at $0.16 per share on revenue of $98.97 million.
&bull; Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) is projected to report quarterly loss at $0.47 per share on revenue of $249.64 million.
&bull; Postal Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTL#NYSE">PSTL</a>) is projected to report earnings for its fourth quarter.
&bull; PowerSchool Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWSC#NYSE">PWSC</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $183.44 million.
&bull; SBA Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) is likely to report quarterly earnings at $1.37 per share on revenue of $682.17 million.
&bull; SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) is projected to report earnings for its fourth quarter.
&bull; Solaris Oilfield Infra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOI#NYSE">SOI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $65.55 million.
&bull; TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) is projected to report quarterly loss at $0.03 per share on revenue of $68.51 million.
&bull; Vitesse Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTS#NYSE">VTS</a>) is likely to report quarterly earnings at $0.43 per share on revenue of $61.81 million.
&bull; Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) is estimated to report quarterly earnings at $1.00 per share on revenue of $522.45 million.
&bull; Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) is projected to report quarterly loss at $0.15 per share on revenue of $17.68 million.
&bull; Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) is expected to report quarterly earnings at $1.17 per share on revenue of $274.44 million.
&bull; Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $183.35 million.
&bull; Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $26.39 million.
&bull; Heico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) is estimated to report quarterly earnings at $0.74 per share on revenue of $894.28 million.
&bull; Primoris Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) is likely to report quarterly earnings at $0.67 per share on revenue of $1.55 billion.
&bull; Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) is likely to report quarterly earnings at $1.47 per share on revenue of $1.92 billion.
&bull; Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is likely to report quarterly loss at $0.09 per share on revenue of $41.74 million.
&bull; EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) is projected to report quarterly loss at $0.32 per share on revenue of $49.81 million.
&bull; SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) is expected to report quarterly loss at $0.28 per share on revenue of $37.61 million.
&bull; Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) is projected to report quarterly loss at $0.02 per share on revenue of $245.82 million.
&bull; Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $193.29 million.
&bull; Adtran Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $228.30 million.
&bull; RLJ Lodging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLJ#NYSE">RLJ</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $314.28 million.
&bull; KNOT Offshore Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNOP#NYSE">KNOP</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $71.33 million.
&bull; ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) is expected to report quarterly earnings at $1.21 per share on revenue of $5.89 billion.
&bull; Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) is likely to report quarterly loss at $0.42 per share on revenue of $564.02 million.
&bull; Everbridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVBG#NASDAQ">EVBG</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $114.66 million.
&bull; MidCap Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIC#NASDAQ">MFIC</a>) is expected to report quarterly earnings at $0.43 per share on revenue of $67.63 million.
&bull; Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is projected to report quarterly earnings at $1.15 per share on revenue of $1.13 billion.
&bull; Heidrick &amp; Struggles Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSII#NASDAQ">HSII</a>) is estimated to report quarterly earnings at $0.68 per share on revenue of $248.12 million.
&bull; SkyWater Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYT#NASDAQ">SKYT</a>) is projected to report quarterly loss at $0.12 per share on revenue of $74.84 million.
&bull; FS KKR Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>) is estimated to report quarterly earnings at $0.75 per share on revenue of $453.28 million.
&bull; CrossAmerica Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAPL#NYSE">CAPL</a>) is expected to report quarterly earnings at $0.22 per share on revenue of $1.11 billion.
&bull; PubMatic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PUBM#NASDAQ">PUBM</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $78.20 million.
&bull; MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $666.70 million.
&bull; Albany Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) is expected to report quarterly earnings at $0.82 per share on revenue of $298.26 million.
&bull; New Mountain Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMFC#NASDAQ">NMFC</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $93.28 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

FibroGen Stock (NASDAQ:FGEN), Short Interest Report

People Also Watch